niacinamide has been researched along with Fatty Liver, Nonalcoholic in 17 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We describe a case of acute liver failure in a patient with advanced hepatocellular carcinoma related to nonalcoholic steatohepatitis during sorafenib treatment." | 7.81 | Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib. ( Bellentani, S; Biasco, G; Brandi, G; De Lorenzo, S; Di Girolamo, S; Saccoccio, G, 2015) |
| "Sorafenib is a small molecular inhibitor of intracellular tyrosine and serine/threonine protein kinases (VEGFR, PDGFR, CRAF and BRAF), and is thought also to induce autophagy, a chief mechanism influencing tumor growth." | 6.53 | Biology, Epidemiology, Clinical Aspects of Hepatocellular Carcinoma and the Role of Sorafenib. ( Grieco, A; Mazzoccoli, G; Miele, L; Oben, J; Vinciguerra, M, 2016) |
| "We describe a case of acute liver failure in a patient with advanced hepatocellular carcinoma related to nonalcoholic steatohepatitis during sorafenib treatment." | 3.81 | Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib. ( Bellentani, S; Biasco, G; Brandi, G; De Lorenzo, S; Di Girolamo, S; Saccoccio, G, 2015) |
| " In addition, increased hepatic microvasculatures compliance-related improved buffering effect of portal vein to acute mannitol infusion was associated with decreased circulating nitric oxide and aldosterone, plasma volume expansion (dye dilution method), splanchnic blood pooling ((99 m) Tc-RBC SPECT/PET/CT scans), peripheral hypotension, portal hypertension and ascites in brivanib and sorafenib-treated NASH-cirrhotic rats." | 3.80 | Anti-VEGFR agents ameliorate hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat. ( Hsieh, YC; Huang, YT; Lee, FY; Lee, KC; Lee, PC; Lee, WP; Lin, HC; Liu, RS; Tan, TW; Yang, YY; Yeh, YC, 2014) |
| "Sorafenib is a small molecular inhibitor of intracellular tyrosine and serine/threonine protein kinases (VEGFR, PDGFR, CRAF and BRAF), and is thought also to induce autophagy, a chief mechanism influencing tumor growth." | 2.53 | Biology, Epidemiology, Clinical Aspects of Hepatocellular Carcinoma and the Role of Sorafenib. ( Grieco, A; Mazzoccoli, G; Miele, L; Oben, J; Vinciguerra, M, 2016) |
| "Non-alcoholic fatty liver disease (NAFLD) caused by consumption of high levels of fat and sugars (HFHS) in diet is considered one of the most dangerous medical complications among children and adolescents." | 1.56 | Nicotinamide and ascorbic acid nanoparticles against the hepatic insult induced in rats by high fat high fructose diet: A comparative study. ( Abd-Allah, H; Ahmed, RF; Ahmed-Farid, OAH; Bakeer, RM; Ibrahim, BMM; Nasr, M, 2020) |
| "Nonalcoholic fatty liver disease (NAFLD) has emerged as an important cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC)." | 1.43 | Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients: Applicability of the BCLC Staging System. ( Alencar, RS; Alvares-da-Silva, MR; Alves, VA; Campos, PB; Carrilho, FJ; Chagas, AL; Diniz, MA; Kikuchi, L; Oliveira, CP; Ratziu, V; Santos, GR; Stefano, JT; Tani, CM; Vezozzo, DC, 2016) |
| "Sorafenib treatment restored mitochondrial function and reduced collagen deposition by nearly 63% compared to the NASH group." | 1.42 | Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model. ( Barbeiro, DF; Bida, PM; Carrilho, FJ; Coelho, AM; Cogliati, B; D'Albuquerque, LA; Kubrusly, MS; Mazo, DF; Oliveira, CP; Pereira, IV; Souza, HP; Stefano, JT; Torres, MM; Xerfan, MP, 2015) |
| "Sorafenib was acutely administered to NASH rats with IR liver injury that were or were not chronically pretreated with the Rho-kinase-specific inhibitor fasudil." | 1.38 | Rho-kinase-dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis. ( Chan, CC; Huang, YT; Lee, KC; Lee, TY; Lin, HC; Yang, YY; Yeh, YC, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (64.71) | 24.3611 |
| 2020's | 6 (35.29) | 2.80 |
| Authors | Studies |
|---|---|
| Yadav, Y | 1 |
| Dunagan, K | 1 |
| Khot, R | 1 |
| Venkatesh, SK | 1 |
| Port, J | 1 |
| Galderisi, A | 1 |
| Cobelli, C | 1 |
| Wegner, C | 1 |
| Basu, A | 1 |
| Carter, R | 1 |
| Basu, R | 1 |
| Zhang, C | 1 |
| Bjornson, E | 1 |
| Arif, M | 1 |
| Tebani, A | 1 |
| Lovric, A | 1 |
| Benfeitas, R | 1 |
| Ozcan, M | 1 |
| Juszczak, K | 1 |
| Kim, W | 1 |
| Kim, JT | 1 |
| Bidkhori, G | 1 |
| Ståhlman, M | 1 |
| Bergh, PO | 1 |
| Adiels, M | 1 |
| Turkez, H | 1 |
| Taskinen, MR | 1 |
| Bosley, J | 1 |
| Marschall, HU | 1 |
| Nielsen, J | 1 |
| Uhlén, M | 1 |
| Borén, J | 1 |
| Mardinoglu, A | 1 |
| Olaniyi, KS | 1 |
| Amusa, OA | 1 |
| Abd-Allah, H | 1 |
| Nasr, M | 1 |
| Ahmed-Farid, OAH | 1 |
| Ibrahim, BMM | 1 |
| Bakeer, RM | 1 |
| Ahmed, RF | 1 |
| Yokouchi, C | 1 |
| Nishimura, Y | 1 |
| Goto, H | 1 |
| Sato, M | 1 |
| Hidoh, Y | 1 |
| Takeuchi, K | 1 |
| Ishii, Y | 1 |
| Méndez-Lara, KA | 1 |
| Rodríguez-Millán, E | 1 |
| Sebastián, D | 1 |
| Blanco-Soto, R | 1 |
| Camacho, M | 1 |
| Nan, MN | 1 |
| Diarte-Añazco, EMG | 1 |
| Mato, E | 1 |
| Lope-Piedrafita, S | 1 |
| Roglans, N | 1 |
| Laguna, JC | 1 |
| Alonso, N | 1 |
| Mauricio, D | 1 |
| Zorzano, A | 1 |
| Villarroya, F | 1 |
| Villena, JA | 1 |
| Blanco-Vaca, F | 1 |
| Julve, J | 1 |
| Lo Re, O | 1 |
| Panebianco, C | 1 |
| Porto, S | 1 |
| Cervi, C | 1 |
| Rappa, F | 1 |
| Di Biase, S | 1 |
| Caraglia, M | 1 |
| Pazienza, V | 1 |
| Vinciguerra, M | 2 |
| Mejía, SÁ | 1 |
| Gutman, LAB | 1 |
| Camarillo, CO | 1 |
| Navarro, RM | 1 |
| Becerra, MCS | 1 |
| Santana, LD | 1 |
| Cruz, M | 1 |
| Pérez, EH | 1 |
| Flores, MD | 1 |
| Pham, TX | 1 |
| Bae, M | 1 |
| Kim, MB | 1 |
| Lee, Y | 1 |
| Hu, S | 1 |
| Kang, H | 1 |
| Park, YK | 1 |
| Lee, JY | 1 |
| Yang, YY | 2 |
| Liu, RS | 1 |
| Lee, PC | 1 |
| Yeh, YC | 2 |
| Huang, YT | 2 |
| Lee, WP | 1 |
| Lee, KC | 2 |
| Hsieh, YC | 1 |
| Lee, FY | 1 |
| Tan, TW | 1 |
| Lin, HC | 2 |
| Yoshiji, H | 1 |
| Noguchi, R | 1 |
| Namisaki, T | 1 |
| Moriya, K | 1 |
| Kitade, M | 1 |
| Aihara, Y | 1 |
| Douhara, A | 1 |
| Kawaratani, H | 1 |
| Nishimura, N | 1 |
| Fukui, H | 1 |
| Kikuchi, L | 1 |
| Oliveira, CP | 2 |
| Alvares-da-Silva, MR | 1 |
| Tani, CM | 1 |
| Diniz, MA | 1 |
| Stefano, JT | 2 |
| Chagas, AL | 1 |
| Alencar, RS | 1 |
| Vezozzo, DC | 1 |
| Santos, GR | 1 |
| Campos, PB | 1 |
| Alves, VA | 1 |
| Ratziu, V | 1 |
| Carrilho, FJ | 2 |
| Brandi, G | 1 |
| De Lorenzo, S | 1 |
| Di Girolamo, S | 1 |
| Bellentani, S | 1 |
| Saccoccio, G | 1 |
| Biasco, G | 1 |
| Pereira, IV | 1 |
| Torres, MM | 1 |
| Bida, PM | 1 |
| Coelho, AM | 1 |
| Xerfan, MP | 1 |
| Cogliati, B | 1 |
| Barbeiro, DF | 1 |
| Mazo, DF | 1 |
| Kubrusly, MS | 1 |
| D'Albuquerque, LA | 1 |
| Souza, HP | 1 |
| Koh, EH | 1 |
| Kim, AR | 1 |
| Kim, H | 1 |
| Kim, JH | 1 |
| Park, HS | 1 |
| Ko, MS | 1 |
| Kim, MO | 1 |
| Kim, HJ | 1 |
| Kim, BJ | 1 |
| Yoo, HJ | 1 |
| Kim, SJ | 1 |
| Oh, JS | 1 |
| Woo, CY | 1 |
| Jang, JE | 1 |
| Leem, J | 1 |
| Cho, MH | 1 |
| Lee, KU | 1 |
| Mazzoccoli, G | 1 |
| Miele, L | 1 |
| Oben, J | 1 |
| Grieco, A | 1 |
| Lee, TY | 1 |
| Chan, CC | 1 |
1 review available for niacinamide and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Biology, Epidemiology, Clinical Aspects of Hepatocellular Carcinoma and the Role of Sorafenib.
Topics: Animals; Autophagy; Carcinoma, Hepatocellular; Clinical Trials as Topic; Female; Genetic Predisposit | 2016 |
1 trial available for niacinamide and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Inhibition of 11β-Hydroxysteroid dehydrogenase-1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, phase II study.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; | 2022 |
15 other studies available for niacinamide and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against non-alcoholic fatty liver disease.
Topics: Acetylcysteine; Adult; Animals; Carnitine; Dietary Supplements; Drug Therapy, Combination; Healthy V | 2020 |
Sodium acetate-mediated inhibition of histone deacetylase alleviates hepatic lipid dysregulation and its accompanied injury in streptozotocin-nicotinamide-induced diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Histone Deacetylase Inhibitors; Inflammation Mediators; Li | 2020 |
Nicotinamide and ascorbic acid nanoparticles against the hepatic insult induced in rats by high fat high fructose diet: A comparative study.
Topics: Animals; Antioxidants; Ascorbic Acid; Biomarkers; Diet, High-Fat; Dietary Supplements; Fructose; Mal | 2020 |
Reduction of fatty liver in rats by nicotinamide via the regeneration of the methionine cycle and the inhibition of aldehyde oxidase.
Topics: Administration, Oral; Aldehyde Oxidase; Animals; Disease Models, Animal; Drug Synergism; Drug Therap | 2021 |
Nicotinamide Protects Against Diet-Induced Body Weight Gain, Increases Energy Expenditure, and Induces White Adipose Tissue Beiging.
Topics: Adipocytes, Beige; Adipose Tissue, Brown; Adipose Tissue, White; AMP-Activated Protein Kinases; Anim | 2021 |
Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of Sorafenib in hepatocellular cancer cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relatio | 2018 |
Nicotinamide prevents sweet beverage-induced hepatic steatosis in rats by regulating the G6PD, NADPH/NADP
Topics: Animals; Beverages; Fructose; Gene Expression Regulation, Enzymologic; Glucose; Glucosephosphate Deh | 2018 |
Nicotinamide riboside, an NAD+ precursor, attenuates the development of liver fibrosis in a diet-induced mouse model of liver fibrosis.
Topics: Animals; Body Weight; Collagen; Diet, High-Fat; Dietary Supplements; Disease Models, Animal; Energy | 2019 |
Anti-VEGFR agents ameliorate hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat.
Topics: Alanine; Animals; Ascites; Cytokines; DNA Primers; Fatty Liver; Fibroblast Growth Factors; Microcirc | 2014 |
Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anticarcinogenic Agents; Antineoplastic Combined C | 2014 |
Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients: Applicability of the BCLC Staging System.
Topics: Ablation Techniques; Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Carcinoma, H | 2016 |
Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Fatal Outcome; Humans; Jaundice; Liver Failu | 2015 |
Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model.
Topics: Animals; Chaperonin 60; Diet, High-Fat; Diethylnitrosamine; Disease Models, Animal; Fibrillar Collag | 2015 |
11β-HSD1 reduces metabolic efficacy and adiponectin synthesis in hypertrophic adipocytes.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 3T3-L1 Cells; Adamantane; Adiponectin; Adipose Tissue, | 2015 |
Rho-kinase-dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis.
Topics: Animals; Apoptosis; Disease Models, Animal; Fatty Liver; Gene Expression Regulation, Enzymologic; He | 2012 |